Bristol-Myers Squibb stock trades near 52-week high as institutions add shares and earnings beat expectations
Published on 08/24/2026 at 23:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol-Myers Squibb Inc. (ISIN US1078421011) stock is trading around $67 as of August 24, 2026, close to its 52-week high after the company beat quarterly earnings expectations and attracted new institutional money in recent regulatory filings.
Institutions build positions as shares track higher
Recent filings show multiple institutional investors initiating or expanding positions in Bristol-Myers Squibb during the second quarter of 2026. One asset manager disclosed the purchase of 384,190 shares valued at $22.14 million, while another reported acquiring 289,321 shares worth $16.7 million, highlighting growing interest in the stock at current levels. Institutional ownership is reported at more than three-quarters of the free float, suggesting that large, long-term investors play a significant role in trading and liquidity. As of August 24, 2026, market data indicate that Bristol-Myers Squibb shares opened around $67.06 on the New York Stock Exchange, close to a 1-year high of $68.64 and comfortably above the 1-year low of $42.52, positioning the stock in the upper end of its recent trading range and reflecting a strong recovery from earlier troughs.
A separate overview of performance as of August 24, 2026, shows that Bristol-Myers Squibb has delivered a year-to-date total return of 28.95%, significantly ahead of the 11.79% gain for the broad S&P 500 index over the same period. That spread of more than 17 percentage points underscores that the stock has outperformed the wider US equity market in 2026, a notable achievement for a large-cap biopharmaceutical name that historically has traded as a defensive holding.
Earnings beat and guidance support valuation
On the fundamentals side, Bristol-Myers Squibb last reported quarterly earnings on July 30, 2026, covering its most recent period. For that quarter, the company posted earnings per share of $2.04, well above the consensus estimate of $1.60, delivering a positive surprise of $0.44 per share. In the same quarter a year earlier, earnings per share stood at $1.46, meaning EPS rose by $0.58 year over year, an increase of nearly 40% when comparing the two periods.
Quarterly revenue for the July 30, 2026 report came in at $12.97 billion, exceeding analysts’ expectations of $11.74 billion by $1.23 billion. Revenue was 5.7% higher than in the year-ago quarter, where sales had been lower by that margin, showing that top-line growth is contributing alongside margin and efficiency gains. The company reported a net margin of 18.87% for the quarter and a return on equity of 66.90%, metrics that point to strong profitability and capital efficiency for a mature pharmaceutical portfolio.
For the full fiscal year 2026, Bristol-Myers Squibb has issued guidance in the form of non-GAAP earnings targets. One recent analysis cites a 2026 non-GAAP EPS range of $6.05 to $6.35 in the broader sector context, while the company itself has set formal guidance at 6.75 to 7.00 EPS for the year. Research analysts currently expect earnings of 6.95 per share for fiscal 2026, which sits in the upper half of that internal guidance band and slightly above some external scenario ranges. Taken together, the guidance and consensus imply that at a stock price in the mid-$60s, Bristol-Myers Squibb is trading on a low-teens forward earnings multiple, which many investors view as a reasonable valuation for a large-cap biopharma with a diversified portfolio and steady cash flows.
Dividend income remains part of the investment case. Bristol-Myers Squibb has declared a quarterly dividend of $0.63 per share, which was paid early in August 2026 to stockholders of record in early July. On an annualized basis that payout amounts to $2.52 per share and, measured against the current share price around $67, corresponds to a dividend yield close to 3.8%. That level compares favorably with yields on many other large pharmaceutical companies and offers investors a recurring income stream alongside capital appreciation potential.
Analyst targets and recent rating actions
Coverage from equity analysts has remained constructive. Data compiled from recent reports show that Bristol-Myers Squibb currently carries a consensus rating described as “Moderate Buy”, based on a mix of Strong Buy, Buy, Hold and a small number of Sell recommendations. Across this coverage universe, the average price target stands at $66.06 per share, only slightly below the current market price near $67, suggesting that the shares are trading close to the central point of analyst valuation models.
Within that broader consensus, one major investment bank has moved its target higher. A late August 2026 strategy piece on defensive healthcare names notes that this bank recently raised its target price for Bristol-Myers Squibb from $67 to $73 per share, framing the stock as a core holding for investors seeking stable dividends and exposure to pharmaceutical pipelines. That new target sits well above the $66.06 average across coverage and roughly $6 higher than the previous benchmark from the same institution, signaling rising confidence in earnings durability and the company’s positioning within the sector.
Market commentary also draws attention to valuation. A sector-focused overview points out that, based on 2026 non-GAAP EPS estimates around the low- to mid-$6 range, Bristol-Myers Squibb trades close to 11 times forward earnings at current share prices. In the context of large-cap US equities, and particularly relative to the broader healthcare and pharmaceutical peer group, that multiple is viewed as moderate rather than aggressive, especially when combined with the company’s dividend yield around 3.8% and its track record of cash generation.
Share performance, trading metrics and volatility
From a trading standpoint, recent quote snapshots offer additional detail. In the August 24, 2026 session, a real-time market-data overview showed Bristol-Myers Squibb shares at $67.28 at 4:00 p.m. ET, unchanged in the subsequent after-hours indication. The same snapshot highlighted that trailing total returns as of August 24, 2026 incorporate both price appreciation and dividend distributions, underpinning the 28.95% year-to-date figure mentioned earlier.
Another intraday view published on August 24, 2026 reports that Bristol-Myers Squibb stock was priced at $67.02 during the trading session, with a daily high of $67.55 and a daily low of $65.13. At that moment the price was 2.9% above the low and 0.8% below the high, showing that the shares spent much of the day towards the upper end of their intraday range. Trading volume reached 6.84 million shares against an average daily volume of 9.16 million, indicating active but not extreme turnover.
These trading metrics matter for investors assessing liquidity and volatility. The 1-year range between the low of $42.52 and the high of $68.64 illustrates a substantial recovery in the share price over the past 12 months, with the current level just a little below the top of that band. Coupled with the double-digit year-to-date total return, the data show that Bristol-Myers Squibb has moved from earlier discounted levels to valuations that more fully reflect its earnings power and dividend stream.
Institutional flows and sector positioning
The recent institutional buying is part of a broader pattern in the stock. Several filings dated August 24, 2026 detail new or increased positions in Bristol-Myers Squibb across different asset managers. One report describes an investment firm acquiring 42,000 shares valued at $2.42 million, another mentions a smaller advisory company purchasing more than 14,900 shares worth $932,000, while a further filing highlights an international asset manager taking a new stake. The figures vary by institution but point in the same direction: capital is being deployed into Bristol-Myers Squibb at current prices.
Commentary accompanying these filings notes that, across the shareholder base, institutional investors collectively own more than three-quarters of Bristol-Myers Squibb’s outstanding shares. Large passive vehicles and long-only funds appear prominently among the top holders, which typically supports trading depth and may dampen share price swings compared with more thinly held small-cap names. For retail investors, this high degree of institutional participation signals that professional market participants view the stock as a core component of diversified healthcare and income strategies.
Sector overviews continue to place Bristol-Myers Squibb among leading global biopharmaceutical companies. The firm operates across oncology, hematology, immunology, cardiovascular disease, neuroscience and other therapeutic areas, with a portfolio that combines established blockbusters with newer pipeline assets. In defensive sector lists for late summer 2026, Bristol-Myers Squibb features as a representative healthcare name, thanks to its combination of earnings visibility, dividend yield and a valuation multiple that has not fully re-rated to growth-stock levels despite the strong share performance year to date.
Pivotal therapies and product focus
One of Bristol-Myers Squibb’s most notable products is the immuno-oncology therapy Opdivo, which has become a cornerstone treatment across several cancer indications. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that works by helping the body’s own immune system recognize and attack tumor cells more effectively. Over the past years it has gained approvals in conditions such as advanced melanoma, non-small cell lung cancer, renal cell carcinoma and other malignancies, often in combination with other agents.
From a business perspective, Opdivo represents a significant revenue contributor and a key driver of the company’s oncology franchise. Its broad label and ongoing clinical development program support a durable stream of sales, while patent life and competition dynamics are central to investor analysis of long-term earnings. Together with other major brands in areas like hematology and cardiovascular disease, Opdivo helps underpin Bristol-Myers Squibb’s cash generation, which in turn supports dividends, share repurchases when they occur and reinvestment in new research and development.
Closing stock perspective
Bristol-Myers Squibb stock is listed on the New York Stock Exchange under the ticker BMY and trades in US dollars. As of August 24, 2026, recent quote data show the shares changing hands in the $67 range, close to their 1-year high and well above the 1-year low, with a year-to-date total return of 28.95% that surpasses the broader market and a dividend yield around 3.8% backed by a $0.63 quarterly payment.
Fact box
Company: Bristol-Myers Squibb Inc.
ISIN: US1078421011
Ticker: BMY
Exchange: New York Stock Exchange
Market cap: $136.89 billion (as of August 24, 2026)
Sector / Industry: Healthcare / Pharmaceuticals and biotechnology
Index membership: S&P 500
